The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Blockhead09-06

Biotech stocks hit a two-year high in mid-July on a spate of promising clinical news, though acquisition activity has slowed significantly from the first part of the year. ↑ X CRSP Stock On ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465618206?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2018/12/stock-medical-trials-01-adobe-150x150.jpg","is_english":true,"pubTime":"2024-09-06 00:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465618206","market":"us","top_or_hot":-1,"title":"The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks","media":"Blockhead","content":"<div>\n<p>Biotech stocks hit a two-year high in mid-July on a spate of promising clinical news, though acquisition activity has slowed significantly from the first part of the year.\n\n\n\n↑\nX\n\n\n\n\nCRSP Stock On ...</p>\n\n<a href=\"https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Cream Of The Crop: 5 Biotechs That Outrank Most Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-06 00:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks hit a two-year high in mid-July on a spate of promising clinical news, though acquisition activity has slowed significantly from the first part of the year.\n\n\n\n↑\nX\n\n\n\n\nCRSP Stock On ...</p>\n\n<a href=\"https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/","article_id":"2465618206","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/12/stock-medical-trials-01-adobe-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465618206","pubTimestamp":1725554318,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4550":"红杉资本持仓","LU0238689110.USD":"贝莱德环球动力股票基金","MRK":"默沙东","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","HALO":"奥洛兹美医疗","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","PFE":"辉瑞","UTHR":"美国联合医疗","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","RHHBY":"罗氏控股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BNTX":"BioNTech SE","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","BK4535":"淡马锡持仓","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4548":"巴美列捷福持仓","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","VRNA":"维罗纳制药","JNJ":"强生","MRNA":"Moderna, Inc.","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","03165":"华夏欧优股对冲","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","ADMA":"ADMA Biologics Inc","LGND":"Ligand Pharmaceuticals Inc.","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"精英：排名超过大多数股票的5家生物技术公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"VRNA":1,"UTHR":1,"RHHBY":1,"MRNA":1,"MRK":1,"LGND":1,"JNJ":1,"HALO":1,"CPRX":1,"BNTX":1,"PFE":0.9,"03165":0.6},"content_text":"Biotech stocks hit a two-year high in mid-July on a spate of promising clinical news, though acquisition activity has slowed significantly from the first part of the year.\n\n\n\n↑\nX\n\n\n\n\nCRSP Stock On Wild Ride After FDA's Historic Approval. These Gene Editing Treatments Could Come Next.\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nCRSP Stock On Wild Ride After FDA's Historic Approval. These Gene Editing Treatments Could Come Next.\n\n\n\n\nIn 2020, the industry was thrust into the pandemic limelight as Pfizer (PFE) and its partner BioNTech (BNTX), along with Moderna (MRNA) and Johnson & Johnson (JNJ), launched a trio of Covid vaccines. But as society learned to live with Covid — and other concerns around the economy and politics took center stage — interest in biotech fell by the wayside.\nInvestors returned to the biotech universe in late 2023 and early 2024 as Big Pharma began putting its dry powder to work on takeovers. Acquisition momentum slowed and biotech stocks traded sideways for months. On July 16, the 730-company biotech industry group hit its highest point since July 2022. After tumbling through early August, shares are now on the rise yet again.\nThe industry group has a Relative Strength Rating of 78, according to IBD Digital. This means the industry group now ranks in the top 22% of all industry groups in terms of 12-month performance.\nThe biotech group ranks No. 50 out of 197 industry groups that IBD tracks. Meanwhile, the pharma group ranks No. 78.\nBut it's key to watch specific measures when examining stocks. In terms of fundamental and technical metrics, the best biotech stocks trading above 10 right now are:\n\nHalozyme Therapeutics (HALO)\nUnited Therapeutics (UTHR)\nLigand Pharmaceuticals (LGND)\nADMA Biologics (ADMA)\nCatalyst Pharmaceuticals (CPRX)\n\nThis Biotech Stock Gets Under Your Skin\nHalozyme Therapeutics is an expert in drug delivery.\nThe company is known for its Enhanze technology, which helps deliver drugs under the skin via a subcutaneous injection. The technology is behind some of the biggest medicines on the market, including Johnson & Johnson's Darzalex Faspro and Roche's (RHHBY) Herceptin.\nIn the second quarter, Halozyme earned an adjusted 91 cents per share on $231.4 million in sales, up a respective 23% and 5% year over year. Both metrics beat expectations.\nThe biotech stock popped more than 4% on Aug. 7, the day Halozyme reported its second-quarter earnings.\nThe company kept its full-year guidance. In June, Halozyme guided to adjusted earnings of $3.65 to $4.05 a share and $935 million to $1.02 billion in sales in 2024. That was based on a new European patent covering the Enhanze technology. The patent is validated in 37 European countries and expires in March 2029.\nHalozyme stock has a strong Composite Rating of 97, and a strong Relative Strength Rating of 96.\nShares broke out of a cup-with-handle base with a buy point at 42.64 on May 8, according to MarketSurge. Shares surged into the profit-taking zone on June 6. Savvy investors are encouraged to take some profits when a stock rises 20% to 25% above its buy point.\nHalozyme stock is also well above its 50-day and 200-day moving averages, but it's not forming a new base.\nHalozyme is a Tech Leader.\nFocusing On Treatments For PAH\nUnited Therapeutics is another top-rated biotech stock. The company makes a handful of drugs for chronic diseases.\nIts biggest drug is Tyvaso, a treatment for pulmonary arterial hypertension, or PAH. During the June quarter, Tyvaso sales climbed 25% to $398.2 million. But that missed expectations for $403.3 million. The nebulized formulation drove the miss, bringing in $139.9 million in sales vs. forecasts for $150.9 million.\nAnalysts are closely watching United Therapeutics' pipeline. The company now expects to have the results of a final-phase PAH study in 2026 vs. prior expectations for 2025, Leerink Partners analyst Roanna Ruiz said in a recent report.\nThe biotech stock hit a record high intraday on July 25. But shares pulled back dramatically on July 31 following the second-quarter report. The biotech stock is now moving ahead again. United Therapeutics stock has a strong Composite Rating of 98, with a lower Relative Strength Rating of 95.\nUnited Therapeutics stock lands on the Tech Leaders list as well.\nLigand Reports Strong Second Quarter\nLigand Pharmaceuticals remains on the list of leading biotech stocks.\nThe company invests in royalty deals and boasts more than 100 partnered commercial and development-stage programs.\nRecently, Ligand collaborator Merck (MRK) received FDA approval for its pneumococcal vaccine for adults, Capvaxie. Ligand also agreed to acquire Apeiron Biologics for $100 million. The deal includes royalty rights to a cancer treatment called Qarziba. This is the sixth key asset added to Ligand's commercial-stage portfolio since the beginning of 2023.\nLigand partner Verona Pharma (VRNA) also won FDA approval for its inhaled treatment for chronic obstructive pulmonary disease, or COPD. Ligand will receive a low single-digit royalty on worldwide net sales of the drug, Ohtuvayre.\nIn the second quarter, Ligand easily beat expectations with adjusted income of $1.40 per share and $41.5 million in sales. Earnings fell by two pennies year over year, but sales rocketed 57.5%.\nThe biotech stock has a Composite Rating of 95 and a matching Relative Strength Rating. Shares broke out of a cup-with-handle base with an entry at 88.73 on July 8, and are approaching a profit-taking zone. Savvy investors are encouraged to take some profits when a stock rises 20% to 25% above an entry.\nLigand also lands on the IBD Tech Leaders list.\nADMA Stock Continues Rising\nBiotech stock ADMA Biologics is on a run.\nThe company is known for its human immune globulin products. These drugs are intravenous infusions for people with immunodeficiencies.\nShares rocketed 31% on Aug. 9 after the company reported adjusted earnings of 14 cents per share, walloping expectations for 8 cents. Earnings reversed from a year-earlier loss of 2 cents. Sales surged 78% year over year to $107.2 million, and handily topped calls for $86.4 million.\nThe biotech stock is now well above its 50-day and 200-day lines. It has best-possible Relative Strength and Composite ratings of 99. ADMA stock also is trading near a record high.\nThe stock is also on the IBD Tech Leaders list.\nADMA stock also currently tops the IBD 50.\nCatalyst Rejoins Top Biotech Stocks\nCatalyst just rejoined the list of top biotech stocks.\nThe company licenses already or soon-to-be approved treatments for rare diseases and diseases of the central nervous system. Today, the company has three products. Firdapse treats a neuromuscular condition that often affects small cell lung cancer patients. Fycompa is a seizure treatment. Catalyst also has a Duchenne muscular dystrophy drug called Agamree.\nIn the June quarter, Catalyst beat expectations with adjusted earnings of 56 cents per share on $122.7 million in sales. Earnings grew by three pennies year over year, while sales jumped more than 23%.\nThe biotech stock is now well above its 50-day and 200-day moving averages, and has a nearly perfect Composite Rating of 98. Shares also have a Relative Strength Rating of 93.\nCatalyst stock is also a Tech Leader.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nEli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024\nEli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?\nGet Timely Buy & Sell Alerts With IBD Leaderboard\nWant More IBD Insights? Subscribe To Our Investing Podcast!\nOptions Trading: How To Start Using Options; How To Manage Risk","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465618206"}